Total Tau (T Tau) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value |
|---|---|
| Category | Protein Biomarker |
| Target | Total tau protein |
| Sample Type | CSF, Plasma |
| Diseases | Alzheimer's Disease, CTE, TBI, ALS |
| Clinical Utility | Axonal damage, neurodegeneration |
Total tau (t-tau) is a core cerebrospinal fluid (CSF) biomarker that measures the concentration of all tau protein isoforms in the brain[1]. Unlike phosphorylated tau (p-tau), which reflects tau pathology specifically, total tau provides a general marker of neuronal and axonal damage[2].
Tau is a microtubule-associated protein encoded by the MAPT gene (Microtubule-Associated Protein Tau) located on chromosome 17q21[3]. In the human brain, tau exists as six isoforms ranging from 352 to 441 amino acids, generated by alternative splicing of exons 2, 3, and 10. The protein plays essential roles in:
Under pathological conditions, tau becomes hyperphosphylated at multiple sites (over 45 potential phosphorylation sites have been identified), leading to microtubule dysfunction and neurofibrillary tangle formation[4]. The balance between kinase activity (GSK-3β, CDK5) and phosphatase activity (PP2A) regulates tau phosphorylation state.
In AD, CSF t-tau is elevated due to neuronal death and axonal degeneration. It correlates with:
However, t-tau is less specific than p-tau for AD diagnosis, as elevations occur in other neurodegenerative conditions. The combination of t-tau with Aβ42/Aβ40 ratio and p-tau provides optimal diagnostic accuracy[10].
t-Tau is a promising biomarker for:
Studies in professional hockey players have shown elevated t-tau following concussion, with levels remaining elevated for several days post-injury.
| Condition | t-tau Level | p-tau Level | t-tau/p-tau Ratio |
|---|---|---|---|
| Alzheimer's Disease | Elevated | Elevated | Normal |
| FTD | Moderately Elevated | Normal | Elevated |
| DLB | Normal-Elevated | Normal-Elevated | Normal |
| CJD | Very High | Normal | Very High |
This differential diagnostic table highlights the utility of the t-tau/p-tau ratio in distinguishing CJD from other dementias[12].
| Method | Sample Type | Sensitivity | Clinical Use |
|---|---|---|---|
| ELISA | CSF | 10 pg/mL | Clinical |
| Simoa | Plasma/Serum | 0.02 pg/mL | Research/Clinical |
| Mass Spectrometry | CSF | 1 pg/mL | Research |
Recent Phase 3 trials of anti-amyloid antibodies have demonstrated that successful amyloid removal correlates with slower t-tau elevation, suggesting neuronal protection[15].
Total tau (t-tau) is a valuable biomarker for assessing axonal damage and neurodegeneration across multiple neurological conditions. While less specific than phosphorylated tau for Alzheimer's disease diagnosis, t-tau provides important information about disease severity, progression, and treatment response. The development of ultra-sensitive blood-based assays promises to expand the clinical utility of t-tau measurement, potentially enabling screening and monitoring in broader populations.
The study of Total Tau (T Tau) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Evidence from SEA-AD paper analysis on biomarker
Both left and right medial temporal lobes (MTL) are critical DMN regions significantly altered by cognitive decline and can serve as early biomarkers for detecting midlife executive function decline.
Supporting evidence:
Baseline biomarker profiles can predict disease stage of individual patients even in preclinical phases where no clinically detectable cognitive impairment is present
Supporting evidence:
The continuous disease progression scale holds information describing other aspects of disease beyond cognitive deterioration measured by ADAS-Cog
Supporting evidence:
Selection bias in clinical-pathological studies and biomarker studies may explain apparent racial differences in AD pathology and biomarkers
Supporting evidence:
18F T807 PET could serve as a biomarker reflecting both progression of AD tauopathy and emergence of clinical impairment
Supporting evidence:
[5] Chaovalitwongse, W. Art et al. (2017). Network Optimization of Functional Connectivity Within Default Mode Network Regions to Detect Cognitive Decline. https://doi.org/10.1109/TNSRE.2017.2679056
[29] Lars Lau Raket, Alzheimer's Disease Neuroimaging Initiative (2020). Statistical Disease Progression Modeling in Alzheimer Disease. https://doi.org/10.3389/fdata.2020.00024
[49] Johnson, Keith A. et al. (2016). Tau positron emission tomographic imaging in aging and early Alzheimer disease. https://doi.org/10.1002/ana.24546
[50] Lisa L. Barnes (2022). Alzheimer disease in African American individuals: increased incidence or not enough data?. https://doi.org/10.1038/s41582-021-00589-3